Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2019 Sep;7(Suppl 6):S201.
doi: 10.21037/atm.2019.07.16.

Prolonged albumin administration in patients with decompensated cirrhosis: the amount makes the difference

Manuel Tufoni  1 , Giacomo Zaccherini  1 , Paolo Caraceni  1
Affiliations
Editorial

Prolonged albumin administration in patients with decompensated cirrhosis: the amount makes the difference

Manuel Tufoni et al. Ann Transl Med. 2019 Sep.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: G Zaccherini is part of the speakers’ bureau for Octapharma. P Caraceni is part of the speakers’ bureau for Grifols SA, Octapharma AG, Baxalta, Alfa Sigma, Takeda and Kedrion Biopharma, he is consultant for Kedrion Biopharma, he is on the advisory board for Grifols SA and received a research grant from Octapharma AG. M Tufoni has no conflicts of interest to declare.

Figures

Figure 1
Figure 1
Long-term treatment with high dose of albumin (HAlbD), but not with low dose (LAlbD), was able to normalize SA concentration, improve cardiocirculatory stability and function, and suppress pro-inflammatory cytokines. Both HAlbD and LAlbD were not associated with significant changes in hepatic venous pressure gradient. HAlbD, high albumin dosage; LAlbD, low albumin dosage; SA, serum albumin; PRA, plasma renin activity.
See this image and copyright information in PMC

Comment on

  • Effects of Albumin Treatment on Systemic and Portal Hemodynamics and Systemic Inflammation in Patients With Decompensated Cirrhosis.
    Fernández J, Clària J, Amorós A, Aguilar F, Castro M, Casulleras M, Acevedo J, Duran-Güell M, Nuñez L, Costa M, Torres M, Horrillo R, Ruiz-Del-Árbol L, Villanueva C, Prado V, Arteaga M, Trebicka J, Angeli P, Merli M, Alessandria C, Aagaard NK, Soriano G, Durand F, Gerbes A, Gustot T, Welzel TM, Salerno F, Bañares R, Vargas V, Albillos A, Silva A, Morales-Ruiz M, Carlos García-Pagán J, Pavesi M, Jalan R, Bernardi M, Moreau R, Páez A, Arroyo V. Fernández J, et al. Gastroenterology. 2019 Jul;157(1):149-162. doi: 10.1053/j.gastro.2019.03.021. Epub 2019 Mar 22. Gastroenterology. 2019. PMID: 30905652 Clinical Trial.

References

    1. Schrier RW, Arroyo V, Bernardi M, et al. Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology 1988;8:1151-7. 10.1002/hep.1840080532 - DOI - PubMed
    1. Møller S, Bernardi M. Interactions of the heart and the liver. Eur Heart J 2013;34:2804-11. 10.1093/eurheartj/eht246 - DOI - PubMed
    1. Bernardi M, Moreau R, Angeli P, et al. Mechanisms of decompensation and organ failure in cirrhosis: From peripheral arterial vasodilation to systemic inflammation hypothesis. J Hepatol 2015;63:1272-84. 10.1016/j.jhep.2015.07.004 - DOI - PubMed
    1. Iwakiri Y, Groszmann RJ. The hyperdynamic circulation of chronic liver diseases: from the patient to the molecule. Hepatology 2006;43:S121-31. 10.1002/hep.20993 - DOI - PubMed
    1. Clària J, Stauber RE, Coenraad MJ, et al. Systemic inflammation in decompensated cirrhosis: characterization and role in acute-on-chronic liver failure. Hepatology 2016;64:1249-64. 10.1002/hep.28740 - DOI - PubMed